Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Corcept Therapeutics (CORT) Stock Price & Analysis

1,344 Followers

CORT Stock Chart & Stats

$81.93$1.47(1.83%)
At close: 4:00 PM EST
$80$100$120Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$80.92 - $84.19
52-Week Range
$28.66 - $126.38
Previous Close
$80.46
Volume
N/A
Average Volume (3M)
970.08K
Market Cap
$8.70B
Enterprise Value
$9.99B
Total Cash (Recent Filing)
$370.70M
Total Debt (Recent Filing)
$8.99M
Price to Earnings (P/E)
54.6
Beta
0.52
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
1.12
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Earnings Growth

Strong revenue and net-income growth indicate expanding demand and improving operating scale across Corcept’s commercial portfolio. Sustained top-line momentum provides resources to support commercialization and development, while rising earnings strengthen the company’s capacity to fund future growth internally.

Cash Generation And Balance Sheet

Robust free cash flow and minimal leverage give Corcept substantial financial flexibility over the next several quarters. High cash conversion supports internally funded investment in clinical programs and commercialization, while the conservative capital structure reduces refinancing pressure and improves resilience.

Lifyorli Commercial Adoption

Rapid physician and patient adoption gives Corcept a second meaningful commercial growth engine beyond its endocrinology franchise. Increasing repeat prescribing and broader use across oncology settings can support durable revenue expansion as awareness and treatment penetration continue to build.

Bears Say

Operating Margin Compression

Operating-margin compression indicates that higher operating costs or other impacts are absorbing part of the benefit from revenue growth. If this persists, it could limit earnings scalability and reduce the cash available for pipeline investment, commercialization, and other capital-allocation priorities.

Relacorilant Regulatory Execution Risk

The prior complete response letter demonstrates that relacorilant’s regulatory path has already encountered a material setback. Although the resubmitted NDA is under review, another delay or unfavorable decision could postpone a major growth opportunity and increase reliance on existing products.

Product Revenue Concentration

Corcept remains substantially dependent on its established Korlym franchise for revenue, even as Lifyorli expands. Concentration in a limited number of marketed products makes sustained growth more dependent on continued demand, reimbursement access, and successful execution of newer launches and pipeline programs.

Corcept Therapeutics News

CORT FAQ

What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $126.38 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $8.70B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 118 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Nov 03, 2026. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.17.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 1.12.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 108,098,400 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $1.01 in its last earnings report, beating expectations of $0.84. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Hedge funds hold Corcept Therapeutics shares: the largest hedge-fund position in Corcept Therapeutics is 71,884,550 shares, and hedge funds increased their holdings by 520.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology